Life Sciences Opportunities in India & China: From Innovation to Commercialization
September 30, 2009
China and India are emerging as major players in the life sciences industry. Both countries have a wealth of top talent as well as rapidly-improving resources for the industry. Both countries also constitute important current and potential markets for drugs, devices and diagnostics, and are also projected to be major sources of innovation in the not-too-distant future. This panel will explore the significant opportunities in China and India, in terms not only of expanding operations to both countries, but also in terms of working with innovative companies that originate from China and India.
Moderator:
- David A. Charapp, Special Counsel, Foley & Lardner LLP
Panelists:
- Stephen A. Bent, Partner, Foley & Lardner LLP
- Friedhelm Blobel, Ph.D., President, CEO, Director, SciClone Pharmaceuticals
- Kim Kamdar, Ph.D., Principal at Domain Associates
- Sanjay Shukla, M.D., M.S., Chief Executive Officer, RxMD
Related Insights
June 10, 2025
Energy Current
Nuclear Power in 2025 – DOE Loan Programs Office (LPO) at the Forefront
As the U.S. faces surging electricity demand from AI data centers, infrastructure upgrades and decarbonization goals, nuclear energy is…
June 9, 2025
Labor & Employment Law Perspectives
Supreme Court Clarifies Discrimination Test in Unanimous Decision
On June 5, 2025, the U.S. Supreme Court in Ames v. Ohio Department of Youth Services unanimously ruled that a plaintiff bringing an…
June 9, 2025
Labor & Employment Law Perspectives
Pride and Prejudice: Federal Court in Texas Vacates Portions of the EEOC’s Workplace Guidance Protecting LGBTQ+ Employees
On May 15, 2025, the U.S. District Court for the Northern District of Texas issued a significant ruling in State of Texas v. Equal…